Zacks Investment Research
27 Mar 2026, 13:51 UTC · 33w ago
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Impact · against what's priced in
Penumbra's strong clinical trial results and expanded product portfolio provide a positive outlook for revenue growth, though macroeconomic and currency headwinds remain a risk. The news is marginally positive as it confirms the success of recent product launches and clinical adoption.
- PEN+0.50
No priced-in read yet
- In context
The STORM-PE trial results demonstrating the superiority of CAVT combined with anticoagulation, along with the 2025 launches of Ruby XL and the Element Vascular Access System, provide concrete catalysts for physician conversion and revenue growth.
Read from the article alone

Search tags




